Always up to date.
 

Our goal is to develop procedure and anatomy specific devices that lead in collaboration with our customers to predictable and superior treatment outcomes. Read on to learn more about our solutions, priorities, partnerships and how we create sustainable value with our teams.

Page 3 of 23.

Medartis increases sales by 21% (CER) and improves its underlying EBITDA margin to 16%

Demonstrating further market share gains, full-year 2023 sales rose by 20.5%(CER) to CHF 212.0 million. The EMEA region was the driving force with strong growth of 19.8%, exceeding the CHF 100 million...

Read more

Publication of the Annual Report 2023

The integrated Annual Report 2023, consisting of the Management Report, the extended Sustainability Report, the Corporate Governance Report, the Remuneration Report and the Financial Report, can be...

Read more

Medartis launches new APTUS Foot product lines

Making a significant step forward, Medartis launches the new Mid- and Hindfoot 2.8/3.5 and the Fusion 3.5 System as well as the expansion of the Hallux and Midfoot 2.8 System in certain countries. ...

Read more

Page 3 of 23.